US 11,740,243 B2
Early and non invasive method for assessing a subject's risk of having pancreatic ductal adenocarcinoma and methods of treatment of such disease
Kim In-San, Seoul (KR); Philippe Bertolino, Lyons (FR); and Ana Hennino, Lyons (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); UNIVERSITÉ CLAUDE BERNARD—LYON, Villeurbanne (FR); CENTRE LEON BERARD, Lyons (FR); and KIST (KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY), Seoul (KR)
Appl. No. 16/81,462
Filed by INSERM (Institut National de la Sante et de la Recherche Medicale), Paris (FR); Centre National de la Recherche Scientifique (CNRS), Paris (FR); Universite Claude Bernard—Lyon 1, Villeurbanne (FR); Centre Leon Berard, Lyons (FR); and KIST (Korea Institute of Science and Technology), Seoul (KR)
PCT Filed Mar. 15, 2017, PCT No. PCT/EP2017/056150
§ 371(c)(1), (2) Date Aug. 31, 2018,
PCT Pub. No. WO2017/158043, PCT Pub. Date Sep. 21, 2017.
Claims priority of application No. 16305276 (EP), filed on Mar. 15, 2016.
Prior Publication US 2019/0086417 A1, Mar. 21, 2019
Int. Cl. G01N 31/00 (2006.01); G01N 33/53 (2006.01); G01N 33/574 (2006.01)
CPC G01N 33/57438 (2013.01) 12 Claims
 
1. A method of treating a patient afflicted with pancreatic ductal adenocarcinoma having a stroma comprising cancer associated fibroblasts producing transforming growth factor β-induced protein (βig-h3), comprising
selecting an anti-βig-h3 neutralizing antibody capable of binding to stroma-produced βig-h3 protein and inhibiting interaction between stroma-produced βig-h3 protein and αVβ3 integrin,
administering to the patient a therapeutically effective amount of the anti-βig-h3 neutralizing antibody binding to stroma-produced βig-h3 protein and inhibiting interaction between stroma-produced βig-h3 protein and αVβ3 integrin,
obtaining specific binding of said anti-βig-h3 neutralizing antibody to stroma-produced βig-h3,
inhibiting interaction between stroma-produced βig-h3 protein and αVβ3 integrin, and
inhibiting the inhibition of cluster of differentiation 8 (CD8)+T cell activation.